UY24367A1 - Vacunas contra tumores y procedimiento para su produccion - Google Patents

Vacunas contra tumores y procedimiento para su produccion

Info

Publication number
UY24367A1
UY24367A1 UY24367A UY24367A UY24367A1 UY 24367 A1 UY24367 A1 UY 24367A1 UY 24367 A UY24367 A UY 24367A UY 24367 A UY24367 A UY 24367A UY 24367 A1 UY24367 A1 UY 24367A1
Authority
UY
Uruguay
Prior art keywords
production procedure
tumor vaccines
tumor
mhc
peptides
Prior art date
Application number
UY24367A
Other languages
English (en)
Inventor
Walter Schmidt
Max Birnstiel
Tamas Schweighoffer
Peter Steinlein
Michael Buschle
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19543649A external-priority patent/DE19543649C2/de
Priority claimed from DE19607044A external-priority patent/DE19607044A1/de
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Priority to UY24430A priority Critical patent/UY24430A1/es
Publication of UY24367A1 publication Critical patent/UY24367A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Vacuna contra tumores y procedimientos para su producción. La vacuna contra tumores contiene células tumorales de las que al menos una parte presenta por lo menos un haplotipo MHC-I del paciente en la superficie de la célula y que se cargaron con uno o varios péptidos que se fijan a la molécula de MHC-I, de modo que las células tumorales son reconocidas como extranas en el contexto con los péptidos del sistema inmune del paciente y desencadenan una respuesta inmune celular. La carga se efectúa en presencia de un policatión tal como polisina
UY24367A 1995-11-23 1996-11-19 Vacunas contra tumores y procedimiento para su produccion UY24367A1 (es)

Priority Applications (1)

Application Number Priority Date Filing Date Title
UY24430A UY24430A1 (es) 1995-11-23 1997-01-03 Procedimiento para preparar vacuna contra tumores

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19543649A DE19543649C2 (de) 1995-11-23 1995-11-23 Tumorvakzine und Verfahren zu ihrer Herstellung
DE19607044A DE19607044A1 (de) 1996-02-24 1996-02-24 Tumorvakzine und Verfahren zu ihrer Herstellung

Publications (1)

Publication Number Publication Date
UY24367A1 true UY24367A1 (es) 2000-10-31

Family

ID=26020603

Family Applications (2)

Application Number Title Priority Date Filing Date
UY24367A UY24367A1 (es) 1995-11-23 1996-11-19 Vacunas contra tumores y procedimiento para su produccion
UY24430A UY24430A1 (es) 1995-11-23 1997-01-03 Procedimiento para preparar vacuna contra tumores

Family Applications After (1)

Application Number Title Priority Date Filing Date
UY24430A UY24430A1 (es) 1995-11-23 1997-01-03 Procedimiento para preparar vacuna contra tumores

Country Status (24)

Country Link
US (1) US20020085997A1 (es)
EP (1) EP0866851A1 (es)
JP (1) JP2000502052A (es)
KR (1) KR19990067653A (es)
CN (1) CN1202931A (es)
AR (1) AR004341A1 (es)
AU (1) AU720131B2 (es)
BG (1) BG62999B1 (es)
BR (1) BR9611466A (es)
CA (1) CA2238176A1 (es)
CO (1) CO4520254A1 (es)
CZ (1) CZ158998A3 (es)
EE (1) EE03778B1 (es)
HU (1) HUP0000318A3 (es)
NO (1) NO982329D0 (es)
NZ (1) NZ322910A (es)
PL (1) PL188537B1 (es)
RO (1) RO115275B1 (es)
RU (1) RU2206329C2 (es)
SK (1) SK66998A3 (es)
TR (1) TR199800912T2 (es)
TW (1) TW514530B (es)
UY (2) UY24367A1 (es)
WO (1) WO1997019169A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS50101B (sr) 1996-02-24 2009-01-22 Boehringer Ingelheim International Gmbh., Farmaceutski preparati za imunomodulaciju
WO1998033527A2 (en) * 1997-01-31 1998-08-06 Cohen Edward P Cancer immunotherapy with semi-allogeneic cells
EP0904786B1 (en) * 1997-08-22 2004-12-15 Science Park Raf S.p.A. Tumor vaccination by use of autologous or HLA-related antigen presenting cell (APC) transduced with a tumour antigen and a foreign antigen capable of causing an immune reaction
US7014848B1 (en) 1998-03-20 2006-03-21 Genzyme Corporation Enhanced anti-tumor immunity
JP2002506886A (ja) * 1998-03-20 2002-03-05 ジェンザイム・コーポレーション 抗腫瘍免疫亢進
FR2807661A1 (fr) * 2000-04-14 2001-10-19 Univ Nantes Agent et procede pour la simulation de lymphocytes t specifiques et lymphocytes t obtenus
US20060035291A1 (en) * 2001-09-18 2006-02-16 Kyogo Itoh Method of detecting cellular immunity and application thereof to drugs
GB0209896D0 (en) 2002-04-30 2002-06-05 Molmed Spa Conjugate
CN1315536C (zh) * 2002-09-13 2007-05-16 李进 肿瘤抗原疫苗及其制备方法和疫苗组合物
GB0224442D0 (en) 2002-10-21 2002-11-27 Molmed Spa A delivery system
WO2005021029A2 (en) * 2003-08-25 2005-03-10 Agadjanyan Michael G Preventive cancer vaccine based on brother of regulator of imprinted sites molecule (boris)
US7674456B2 (en) * 2004-06-14 2010-03-09 Charles Wiseman Breast cancer cell lines and uses thereof
EP1871166A4 (en) 2005-03-29 2008-11-12 Univ Illinois VACCINES AGAINST CANCER AND THERAPEUTIC METHODS
ATE388164T1 (de) * 2005-09-05 2008-03-15 Immatics Biotechnologies Gmbh Tumor-assoziierte peptide, welche an unterschiedliche menschliche leukozytenantigene der klasse ii binden
US20090004213A1 (en) * 2007-03-26 2009-01-01 Immatics Biotechnologies Gmbh Combination therapy using active immunotherapy
WO2011101465A1 (en) 2010-02-19 2011-08-25 Intercell Ag Ic31 nanoparticles
AU2013289939B2 (en) * 2012-07-12 2018-08-09 Persimmune, Inc. Personalized cancer vaccines and adoptive immune cell therapies
US12065699B2 (en) 2016-03-15 2024-08-20 Repertoire Genesis Incorporation Monitoring and diagnosis for immunotherapy, and design for therapeutic agent
SG11201910101SA (en) 2017-05-08 2019-11-28 Gritstone Oncology Inc Alphavirus neoantigen vectors
CN114072516A (zh) 2019-05-30 2022-02-18 磨石生物公司 经修饰的腺病毒
KR20230046313A (ko) 2020-08-06 2023-04-05 그릿스톤 바이오, 인코포레이티드 다중에피토프 백신 카세트
US20240156869A1 (en) * 2021-03-12 2024-05-16 T-Cure Bioscience, Inc. Methods of enhancing diversity of hla haplotype expression in tumors to broaden tumor cell susceptibility to tcr-t therapy

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6235525B1 (en) * 1991-05-23 2001-05-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof
EP0569678A3 (en) * 1992-03-13 1994-10-26 Yeda Res & Dev Double transfectants of MHC genes as cellular vaccines for immunoprevention of tumor metastasis.

Also Published As

Publication number Publication date
CA2238176A1 (en) 1997-05-29
NO982329D0 (no) 1998-05-22
RU2206329C2 (ru) 2003-06-20
BG62999B1 (bg) 2001-01-31
HUP0000318A3 (en) 2002-02-28
CZ158998A3 (cs) 1999-06-16
BG102439A (en) 1999-01-29
BR9611466A (pt) 1999-05-18
AR004341A1 (es) 1998-11-04
TR199800912T2 (xx) 1998-08-21
NZ322910A (en) 2000-05-26
PL326756A1 (en) 1998-10-26
SK66998A3 (en) 1998-12-02
EP0866851A1 (de) 1998-09-30
EE9800161A (et) 1998-12-15
EE03778B1 (et) 2002-06-17
CO4520254A1 (es) 1997-10-15
JP2000502052A (ja) 2000-02-22
AU720131B2 (en) 2000-05-25
RO115275B1 (ro) 1999-12-30
KR19990067653A (ko) 1999-08-25
WO1997019169A1 (de) 1997-05-29
US20020085997A1 (en) 2002-07-04
HUP0000318A2 (hu) 2000-06-28
UY24430A1 (es) 1997-07-01
TW514530B (en) 2002-12-21
AU7694796A (en) 1997-06-11
CN1202931A (zh) 1998-12-23
PL188537B1 (pl) 2005-02-28

Similar Documents

Publication Publication Date Title
UY24367A1 (es) Vacunas contra tumores y procedimiento para su produccion
ES2055785T3 (es) Peptidos sinteticos y su uso como vehiculos universales para la preparacion de conjugados inmunogenos aptos para el desarrollo de vacunas sinteticas.
DE69734882D1 (de) Dna immunisierung gegen chlamydia infektion
ES2109924T3 (es) Metodo rapido, versatil y simple de expresion de genes en celulas eucarioticas.
DK1448229T3 (da) Farmaceutisk sammensætning til at inducere et immunrespons hos et menneske eller et dyr
GB9804632D0 (en) Virus preparations and methods
AR004545A1 (es) Derivados de purin-6-ona, procedimientos para su preparacion, el uso de los mismos en la preparacion de medicamentos, medicamentos que los contieneny un procedimiento para preparar dichos medicamentos
ATE179614T1 (de) Herpes simplex virus vp16 impfstoffe
HUT62331A (en) Process for producing recombinant avipox virus, cell culture infected with the virus and vaccine deriving from this virus, suitable for vaccinating poultry
BRPI0410562A (pt) molécula recombinante e veìculo para expressão, liberação e purificação de polipeptìdeos alvo
ES2078971T3 (es) Produccion de virus y purificacion de proteinas con envoltura virica para uso en vacunas.
AR018489A1 (es) Uso de una celula realizada geneticamente que comprende dna que codifica una proteina de gen de activacion de linfocito 3 (lag-3) transmembrana y de dicha proteina para la fabricacion de un medicamento util para inducir la proteccion del rechazo de injerto y uso de moleculas antisentido de las misma
DK0889969T3 (da) Rekombinante adenovirale til genterapi af humane tumorer
PT964697E (pt) Aplicacoes terapeuticas de antigenios ou epitopos, associados com um processamento celular de peptidos deficiente, e.g. expressos em celulas rma-s transfectadas com um gene b7-1
AR004567A1 (es) Metodos para detectar la infeccion de t.cruzi, en una muestra biologica, un vector de expresion recombinante, un microorganismo modificado, un kit de diagnostico, una composicion farmaceutica, el uso de la composicion farmaceutica para la preparacion de un medicamento para estimular la produccion de anticuerpos que se liguen a t. cruzi.
EP0236977A3 (en) Bovine virus diarrhea and hog cholera vaccines
SE9903534L (sv) Bärare innehållande ett huvudkapsidprotein L1 från humant papillomavirus samt dess användning
HU9200583D0 (en) Method for producing el peptides of rubeola
SE8604991D0 (sv) Snake venom growth arresting peptide
RU94040393A (ru) Синтетические пептиды для вакцины против краснухи
AR045416A1 (es) Coadyuvante de linfocitos humanos para vacunas
ES2080024B1 (es) Vacuna subunitaria recombinante contra la enfermedad hemorragica virica de los conejos.
AR012944A1 (es) Preparacion de virus de la enfermedad de marek usando lineas de celulas continuas de mamifero
ATE295884T1 (de) Dna-expressionskonstrukt zur behandlung von infektionen mit leishmaniose
AR240063A1 (es) Procedimiento para la produccion del activador del plasminogeno del tejido humano mediante el cultivo de la cepa de celulas registrada como kym-sf ifo 50135.

Legal Events

Date Code Title Description
VENC Patent expired

Effective date: 20161119